Did you mean heat rice construct in sb lal c chicken?
Displaying drugs 11151 - 11175 of 12824 in total
GTI-2501
GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Initial testing has demonstrated strong antitumor...
Investigational
Matched Description: … and in a phase I clinical trial. ... Initial testing has demonstrated strong antitumor activity in preclinical studies in prostate cancer ... The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory …
Paliroden
Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines. Studies show that use of paliroden increased the rate of formation of both neural progenitors and mature neurons. It is indicated for use in Alzheimer's Disease and Parkinson’s.
Investigational
Matched Description: … It is indicated for use in Alzheimer's Disease and Parkinson’s. …
Bedoradrine
Investigational
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Alicaforsen
Investigational
Nelipepimut-S
Investigational
Motavizumab
Investigational
Tifacogin
Investigational
Befunolol
Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.
Experimental
Matched Description: … Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. ... It is currently in experimental status, and is being tested for the management of open angle glaucoma …
Dirithromycin
Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.
Experimental
Alprenolol
One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties.
Experimental
Withdrawn
Matched Description: … Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. …
LX201
LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically...
Investigational
Matched Description: … The implant is being developed clinically for the prevention of rejection in corneal transplantation. ... LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in …
Pumactant
Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
Investigational
Matched Description: … Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. …
XL784
XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied...
Investigational
Matched Description: … the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in …
PSN9301
PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for...
Investigational
LY2181308
LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung,...
Investigational
Matched Description: … LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. ... LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer …
LY2275796
LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
Investigational
Matched Description: … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of …
ACR325
ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects. ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Investigational
Matched Description: … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor …
ABT-510
ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and slows tumor growth. It is developed by Abbott Laboratories for the treatment of Solid Tumors, Lymphoma and Melanoma.
Investigational
Matched Description: … ABT-510 is a peptide mimetic of thrombospondin-1 (TSP-1), blocks angiogenesis in vitro and in vivo, and …
QR-334
QR-334 is under investigation for the treatment of sialorrhea. Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea. The symptom is associated with many diseases including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease,...
Investigational
Matched Description: … Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. …
FX06
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
Investigational
Matched Description: … FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development …
R-851
R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells. It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually...
Investigational
Matched Description: … R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate …
Veglin
VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma. Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.
Investigational
Matched Description: … Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in …
ANZ-100
Investigational
PR-104
Investigational
Displaying drugs 11151 - 11175 of 12824 in total